AFFX Reports Preliminary Results - Analyst Blog
January 10 2013 - 10:34AM
Zacks
Genetic products company, Affymetrix Inc.
(AFFX) provided its guidance for the 2012 fourth quarter results,
based on available preliminary financial data. The company will
report its financial results on January 31, after market
closes.
Affymetrix expects revenues to be $84 million in the quarter,
which is in line with the Zacks Consensus Estimate. Revenues from
the acquired eBioscience business grew 5% year over year,
contributing $18 million to total revenues.
Organically, the company is expected to grow 1% year over year.
For 2012, total sales are estimated to be $295 million, an increase
of 10.3% from the prior year. The Zacks Consensus Estimates for the
fourth quarter and full year 2012 are expected to be a loss of 2
cents and 14 cents per share, respectively.
Affymetrix also announced a restructuring initiative to boost
its bottom-line growth. The company will disembark 100 of its
employees, representing 8% of its workforce. The company will incur
most of the additional cost associated with the restructuring in
the first quarter of 2013, which is expected to be roughly $7
million. Post restructuring, Affymetrix will be able to save
roughly $25 million annually based on its 2013 outlook, of which $5
million is in cost of goods sold.
The company prepaid $9.6 million (the entire principal amount
due in 2013) of its senior-secured debt in December last year,
partly funded by the sale of its Sacramento manufacturing facility.
At the end of 2012, senior debt was $73 million and cash-on-hand
stood at roughly $35 million. Management believes that the
restructuring effort will improve the company’s free cash flow
position in 2013 and quicken repayment of its senior
debt.
Affymetrix also revealed some changes in its top management in
2013. John F. (Rick) Runkel, executive vice president (EVP) and
general counsel, will retire on March 31, 2013, and will be
replaced by Ms. Siang Chin, who joined the company as vice
president, chief corporate counsel in 2007. Additionally, Mr. Tim
Barabe, EVP and CFO will also retire from the company.
Affymetrix is a leading provider of microarray-based products
and services to the global research community. Along with
Illumina Inc. (ILMN), it is one of the two major
providers of microarray technologies, primarily serving the field
of genetic research. The company holds a leading position in the
gene expression products and services market.
Affymetrix is expanding its customer base through new product
launches and strategic alliances. Moreover, the company is pursuing
a number of strategies (including acquisitions and expansion into
new markets) aimed at expanding its top line.
However, research and development spending by Affymetrix’s
customers have fallen considerably due to a weak macroeconomic
environment coupled with stringent government actions including
budget cuts. We currently have a Zacks Rank #2 (Buy) on the
stock.
AFFYMETRIX INC (AFFX): Free Stock Analysis Report
ILLUMINA INC (ILMN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024